ADAP Advocacy issued the following press releases:
National Conference to be held May 29th-31st in Arlington, VA
WASHINGTON, D.C. - (February 15, 2024) - ADAP Advocacy today announced it is a proud organizational partner of SYNChronicity 2024 (SYNC 2024), the Annual National Conference for HIV, HCV, STIs, Harm Reduction, and LGBTQ Health, to be held May 29th-31st in Arlington, Virginia.
Survey Seeks Patient Perspectives from People Who are HIV-Negative on Long-Acting Injectables HIV Pre-Exposure Prevention
WASHINGTON, D.C. - (February 1, 2024) - ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, launched an online survey to gain better patient perspectives from people who are HIV-negative about approved LAI medications for HIV Pre-Exposure Prophylaxis (PrEP). The online survey is open to people who are HIV-Negative and residing in the United States and its Territories.
State AIDS Drug Assistance Program would be raided by $500 million
WASHINGTON, D.C. - (January 16, 2024) - ADAP Advocacy today issued the following statement by CEO Brandon M. Macsata:
"ADAP Advocacy is deeply concerned over California Governor Gavin Newsom’s proposed 2024-2025 budget because it attempts to balance the state’s growing budget deficit by exploiting safety net programs, including the State AIDS Drug Assistance Program (ADAP). A proposed budgetary loan of $500 million from the state’s ADAP Rebate Fund to the General Fund sets a very dangerous precedent in a progressive state, but it represents the latest attempt by politicians to raid ADAP-related funds for things other than providing care and treatment to people living with HIV/AIDS. We’ve already witnessed attempts at the federal level to divert ADAP funding from HIV care to HIV prevention with the greed-drive Ryan White PrEP Availability Act, as well as at the state level, such as New York, trying to manipulate already limited HIV-related funding. ADAP Advocacy urges California lawmakers to oppose any financial shenanigans misusing funds designated for the AIDS Drug Assistance Program."
Federal agency’s approval of the risky drug importation plan potentially puts the health of people living with HIV at risk
WASHINGTON, D.C. - (January 5, 2024) - ADAP Advocacy today issued the following statement by CEO Brandon M. Macsata:
“ADAP Advocacy is disturbed by the U.S. Food & Drug Administration’s deeply flawed decision to approve Florida’s plan to import prescription drugs from Canada. This policy is a particularly acute threat to people living with HIV in the United States and Canada since the list of drugs Florida intends to import includes a disproportionate number of treatments for HIV. Additionally, the safety of HIV medicine has already been in question following one of the largest counterfeiting schemes in our nation’s history. Given Canada’s expressed concerns about participating in importation plans, we are worried patients in Florida will now be at even greater risk for counterfeits. We urge the FDA to reconsider approving Florida's Canadian drug importation program.”